Commercial Metals Company (CMC)
NYSE: CMC · Real-Time Price · USD
50.28
-1.58 (-3.05%)
Aug 1, 2025, 4:00 PM - Market closed
CTI BioPharma Stock Forecast
Stock Price Forecast
The 6 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $58.75, which forecasts a 16.85% increase in the stock price over the next year. The lowest target is $49 and the highest is $75.
Price Target: $58.75 (+16.85%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $52 → $54 | Hold | Maintains | $52 → $54 | +7.40% | Jul 14, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $53 → $58 | Hold | Maintains | $53 → $58 | +14.36% | Jun 25, 2025 |
| BMO Capital | BMO Capital | Hold Maintains $57 → $55 | Hold | Maintains | $57 → $55 | +9.39% | Jun 24, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $48 → $53 | Hold | Maintains | $48 → $53 | +5.41% | Jun 20, 2025 |
| JP Morgan | JP Morgan | Hold Initiates $52 | Hold | Initiates | $52 | +3.42% | May 30, 2025 |
Financial Forecast
Revenue This Year
7.85B
from 7.93B
Decreased by -0.98%
Revenue Next Year
8.49B
from 7.85B
Increased by 8.18%
EPS This Year
3.20
from 4.14
Decreased by -22.79%
EPS Next Year
4.57
from 3.20
Increased by 42.88%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 8.3B | 9.6B | 10.2B |
| Avg | 7.8B | 8.5B | 9.0B |
| Low | 7.6B | 7.8B | 8.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 4.2% | 21.8% | 20.0% |
| Avg | -1.0% | 8.2% | 5.8% |
| Low | -4.6% | -0.0% | -4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.45 | 5.76 | 4.96 |
| Avg | 3.20 | 4.57 | 4.49 |
| Low | 2.93 | 3.59 | 4.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -16.6% | 80.3% | 8.5% |
| Avg | -22.8% | 42.9% | -1.6% |
| Low | -29.1% | 12.2% | -10.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.